MHE Staff

A recent survey on primary care spending showed the U.S. lagging behind.

Tthe FDA approved Kevzara (sarilumab),an interleukin-6 receptor inhibitor, last year. It may help people with polymyalgia rheumatica ease off taking glucocorticoids.

The results of this week’s poll about the Affordable Care Act.

J&J’s Opsynvi is single-tablet combination of macitentan, an endothelin receptor antagonist, and tadalafil, a PDE5 inhibitor. It will be priced on parity with Opsumit, which is also a J&J product to treat patients with PAH.

The 14th anniversary of the Affordable Care Act was this past Saturday.

The results of this week’s poll about whether copay accumulators should be banned.

About 20 states have moved to ban copay accumulators.

PQA is the national quality organization dedicated to improving medication safety, adherence, appropriate use and medication management services.

Povorcitinib, an oral JAK1 inhibitor, shows promise in treating prurigo nodularis, a chronic, inflammatory skin disease.

The results of this week’s poll about Medicare cap extension.

Almost 20,000 dermatologists attended the annual meeting this weekend at the San Diego Convention Center.

The submission is for the same indications, including Xolair’s recently approved indication IgE-mediated food allergy.

The clinical associate professor at the Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, spoke in a session over the weekend at the American Academy Dermatology meeting about conditions that may mimic atopic dermatitis.

Should the Medicare $2,000 per year cap on out-of-pocket costs for prescription drugs be extended to commercial insurance?

In a discussion with Managed Healthcare Executive, Robert Sidbury, M.D., M.P.H, FAAD, professor of pediatrics at the Seattle Children's Hospital talks about what it takes to run a dermatology practice and how to implement value-based care initiatives.

At the American Academy of Dermatology meeting in San Diego, Raj J. Chovatiya, M.D., Ph.D, discussed the evolution of studies on Jak inhibitors post-approval.

The results of this week’s poll about health insurance coverage of GLP-1s for weight loss.

In a discussion with Managed Healthcare Executive, Jonathan I. Silverberg, M.D., Ph.D., M.P.H., an Associate Professor of Dermatology at The George Washington University School of Medicine and Health Sciences, discussed the concept of "atopic march."

John Barbieri, assistant professor at Harvard Medical School, is looking forward to the upcoming 2024 American Academy of Dermatology meeting, which runs from March 8-12 in San Diego. Barbieri is particularly showing interest in late-breaking abstracts and trial data and hoping to see cutting-edge information from pivotal clinical trials.

The research grant will examine barriers to access to continuous glucose monitoring, which is widely seen as having advantages over keeping tabs of blood sugar levels with finger pricks,

Please pick the statement that most closely resembles your view of health insurance coverage of GLP-1s for weight loss.

Both Wyost and Jubbonti are interchangeable for the reference products and are approved for all of the same indications in osteoporosis and bone cancer.

The results of this week’s poll about the recent Change Healthcare Cyberattack.

Christopher Starr, M.D., of Weill Cornell Medical College in New York discusses of the challenges of making a diagnosis and a new treatment.

The Prescription Drug User Fee Act action date is Aug. 28, 2024.

Share your view about the Change Healthcare cyberattack.

The results of this week’s poll about Medicaid work requirements.

Linvoseltamab is bispecific antibody designed to treat relapsed/refractory multiple myeloma. The FDA’s target action date is Aug. 22, 2024